For its leptomeningeal cancer drug, Plus Therapeutics found the FDA receptive to clinical trial endpoints beyond overall survival. The agency was open to "compartmental based endpoints" measuring efficacy within the targeted CNS area—a significant regulatory shift for non-systemic treatments with no established approval pathway.

The field of sarcoma treatment has seen rapid progress by shifting from "one-size-fits-all" clinical trials to studies focused on specific histological subtypes. This targeted approach led to nearly 10 FDA approvals since 2019, revolutionizing care for these rare cancers.

Unlike stem cell transplants, CAR T-cell therapy has less intense conditioning, making it a viable option for patients into their late 80s. Eligibility focuses more on fitness and frailty rather than chronological age, broadening access for a larger patient population.

Instead of waiting years for separate pediatric studies, Syndax integrated children into its initial adult clinical trials. This highly unusual approach, combined with creating child-friendly formulations, enabled them to bring novel medicines to both adults and children simultaneously, addressing a critical need much faster.

The former high-risk group (Stage 3b) was traditionally excluded from major clinical trials. The new staging system demonstrates that these patients have better-than-expected outcomes with modern therapy and should be included in future studies. It simultaneously identifies a new ultra-high-risk group (Stage 3c) that requires entirely different trial designs.

Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.

Unlike most cancers, National Comprehensive Cancer Network (NCCN) guidelines recommend clinical trials as the preferred first-line treatment for glioblastoma patients with good performance status. This rare recommendation highlights the dismal outcomes with existing therapies and the urgent need for therapeutic innovation.

Clinical trials for acute leukemia targeting older or chemotherapy-ineligible patients are enrolling a surprisingly high number of younger individuals. This trend blurs the lines of the intended patient population and affects how trial data should be interpreted and generalized to real-world practice.

Beyond improving progression-free survival, the targeted therapy vorasidenib also provides a significant quality-of-life benefit by improving seizure control. Seizures are a common presenting symptom for low-grade glioma patients, and this added therapeutic effect makes the drug a more holistic treatment option.